Atossa Therapeutics Shares to Trade With Stapled CVRs After Close
Atossa Therapeutics common stock is scheduled to begin trading with stapled contingent value rights after close of business today.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Atossa Therapeutics enters contingent value rights agreement
Atossa said its board approved stapled CVRs tied to potential proceeds from its first qualifying priority review voucher. The rights cover 25% of net proceeds, up to a $50 million aggregate cap.